University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Marion G. Peters, MD

Marion G. Peters, MD

Professor, Department of Medicine, UCSF
John V. Carbone, MD, Endowed Chair in Medicine, UCSF

Cancer Center Program Memberships

Affiliate Member

Education

Melbourne University Medical School, Melbourne, Australia, M.B.B.S., 1972, Medicine
St. Vincent’s Hospital Medical School, Melbourne, Australia, Medicine
Melbourne University, M.D., 1991, Medicine/Immunology


Professional Experience

  • 1973-1978
    Internal Medicine GI training, St. Vincent's Hospital Melbourne, Australia. Royal Melbourne Hospital and The Walter and Eliza Hall Institute of Medical Research, Melbourne Australia
  • 1980-1983
    Visiting Fogarty Fellow, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD
  • 1983-1985
    Visiting Staff Fellow to Liver Disease Section, National Institute of Arthritis, Diabetes and Digestive and Kidney Disease, NIH, Bethesda, MD
  • 1985-1991
    Assistant Professor, Medicine, Microbiology and Immunology, Washington University School of Medicine, St. Louis, MO
  • 1991-1999
    Associate Professor of Medicine, Assistant Professor of Microbiology and Immunology, Washington University School of Medicine, St. Louis, MO
  • 1999-present
    Professor of Medicine, Director of Hepatology Research, UCSF, San Francisco

Honors & Awards

  • Honors in Medicine, Pathology, Obstetrics, & Gynecology
  • Burroughs Wellcome Young Investigator in Virology

Selected Publications

  1. Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology. Clin Liver Dis. 2019 Aug; 23(3):487-492.
    View on PubMed
  2. Sasadeusz J, Grigg A, Hughes PD, Lim SL, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies. Clin Liver Dis. 2019 Aug; 23(3):511-519.
    View on PubMed
  3. Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients. Clin Liver Dis. 2019 Aug; 23(3):493-509.
    View on PubMed
  4. Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents. Clin Liver Dis. 2019 Aug; 23(3):521-534.
    View on PubMed
  5. Clarke WT, Miranda J, Neidich E, Hudock R, Peters MG, Kelly EM. Metabolic syndrome and liver steatosis occur at lower body mass index in US Asian patients with chronic hepatitis B. J Viral Hepat. 2019 May 28.
    View on PubMed
  6. Nápoles TM, Batchelder AW, Lin A, Moran L, Johnson MO, Shumway M, Luetkemeyer AF, Peters MG, Eagen KV, Riley ED. HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era. J Public Health (Oxf). 2019 May 02.
    View on PubMed
  7. Lo Re V, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN. Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients. J Acquir Immune Defic Syndr. 2019 Apr 29.
    View on PubMed
  8. Bowlus CL, Yang GX, Liu CH, Johnson CR, Dhaliwal SS, Frank D, Levy C, Peters MG, Vierling JM, Gershwin ME. Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. J Autoimmun. 2019 Jul; 101:26-34.
    View on PubMed
  9. Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. Clin Infect Dis. 2019 Mar 28.
    View on PubMed
  10. Shumway M, Luetkemeyer AF, Peters MG, Johnson MO, Napoles TM, Riley ED. Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences. AIDS Care. 2019 Mar 04; 1-8.
    View on PubMed
  11. Peters MG. Hepatitis B Virus Infection: What Is Current and New. Top Antivir Med. 2019 Jan; 26(4):112-116.
    View on PubMed
  12. Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. Open Forum Infect Dis. 2019 Jan; 6(1):ofy353.
    View on PubMed
  13. Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latanich R, Wojcik GL, Taub MA, Valencia A, Thomas DL, Duggal P. Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Gastroenterology. 2019 Apr; 156(5):1496-1507.e7.
    View on PubMed
  14. Kardashian A, McKinney J, Huynh N, Yu R, Peters M, Catalli L, Price JC. Post-sustained virologic response liver stiffness may underestimate fibrosis after direct acting antiviral-containing therapy. Clin Infect Dis. 2018 Nov 02.
    View on PubMed
  15. Jhaveri R, Broder T, Bhattacharya D, Peters MG, Kim AY, Jonas MM. Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now. Clin Infect Dis. 2018 Oct 30; 67(10):1493-1497.
    View on PubMed
  16. Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019 Jan 10; 133(2):137-146.
    View on PubMed
  17. Geha RM, Dhaliwal G, Peters MG, Manesh R. A Tough Egg to Crack. J Hosp Med. 2018 09; 13(9):641-645.
    View on PubMed
  18. MacBrayne CE, Marks KM, Fierer DS, Naggie S, Chung RT, Hughes MD, Kim AY, Peters MG, Brainard DM, Seifert SM, Castillo-Mancilla JR, Bushman LR, Anderson PL, Kiser JJ. Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. J Antimicrob Chemother. 2018 Aug 01; 73(8):2112-2119.
    View on PubMed
  19. Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers. 2018 Jun 07; 4:18035.
    View on PubMed
  20. Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis. 2018 Jun; 5(6):ofy103.
    View on PubMed

Go to UCSF Profiles, powered by CTSI